28Jun/13

GlobalData: Upcoming Novartis chronic heart failure drug expected to dominate … – PharmaLive (press release) (subscription)

GlobalData: Upcoming Novartis chronic heart failure drug expected to dominate
PharmaLive (press release) (subscription)
Research and consulting firm GlobalData has released a new report, PharmaPoint: Chronic Heart Failure – Global Drug Forecast and Market Analysis to 2022 and forecasts global sales of Novartis’ combination drug LCZ-696 to reach a massive $1.86 billion 

and more »

28Jun/13

GlobalData Expects New Novartis Heart Failure Drug to Reach $1.9 Billion … – PharmaLive (press release) (subscription)

GlobalData Expects New Novartis Heart Failure Drug to Reach $1.9 Billion
PharmaLive (press release) (subscription)
LONDON, UK (GlobalData), 20 June 2013 – Following a launch scheduled for 2015 for the treatment of Chronic Heart Failure (CHF), Novartis’ novel combination drug LCZ-696 will rapidly dominate the global CHF therapeutics sector and mark a drug